Overview
Mosaic Intelligence Labs is building an AI platform for surgery. It aims to provide AI-native sensing and surgical intelligence to help make surgeries safer and more scalable. The product is described as a multi-intelligence AI operating system where users can install specialized AI variants that work together to perform tasks, focusing on enhanced surgical applications through advanced AI sensing and intelligence capabilities. Compared with competitors, Mosaic emphasizes a modular, collaborative AI ecosystem tailored to medical sensing and surgical workflows, operating in stealth and aiming to deploy AI-driven support across robotic and non-robotic surgical procedures. The overall goal is to improve surgical safety, precision, and scalability in healthcare through an integrated AI medical platform.
Work here?Claim your company
Simplify's take
What believers are saying
- A November 13, 2026 de-stealth event signals product readiness and fundraising momentum.
- The FDA filing shows active regulatory planning for endovascular AI and robotic assistance.
- Team members claim 20-plus publications and prior surgical robot exposure touching 20 million patients.
What critics are saying
- Mosaic is still in stealth, with no public clinical data or cleared product.
- FDA engagement on October 19, 2026 exposes regulatory scrutiny before any commercial proof.
- Intense competition from Intuitive Surgical, J&J, and Medtronic could crush adoption if validation slips.
What makes Mosaic Intelligence unique
- Mosaic Intelligence targets endovascular surgery with sensing, navigation, and robotic assistance, not generic medtech.
- Founders Ileana Pirozzi and Alison Mackanic bring Stanford robotics training and 400-plus patents experience.
- Their perception-first architecture combines patient-specific models, live imaging, and sensor fusion for procedural control.
Help us improve and share your feedback! Did you find this helpful?